h002
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 26, 2022 (NCT05552781)
Timeline
Indications
Mechanism of action
- Sphingosine 1-phosphate receptor 1MODULATOR
S1PR1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06963320 | Phase 2 | Jan 20, 2025 | Livzon Pharmaceutical Group Inc. |
| NCT05519293 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2022 | Parexel, RedCloud Bio |
| NCT05552781 | Phase 1/Phase 2 (Phase 2) | Aug 26, 2022 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RedCloud Bio | For profit | 2 | 2 | 1 | 2022 |
| Livzon Pharmaceutical Group Inc. | For profit | 1 | 1 | 1 | 2025 |
| Parexel | For profit | 1 | 0 | 1 | 2022 |
| R&G Pharma Studies Co.,Ltd. | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1